Hims & Hers Health(HIMS)股价今日盘中大跌5.24%,引发了市场广泛关注。分析师们认为,这与该股此前疯涨有关,估值已经严重超出合理区间。
在过去一年里,HIMS一路狂飙,目前已上涨约205%。其估值曾一度合理,增长潜力巨大。但现在,该股的预期市销率已经高达7.5倍左右,而且每股自由现金流估值约为105倍,远超同行水平,即便考虑其高增长特性,也显得有些过于昂贵了。
另一方面,投资者正翘首以盼HIMS明日将公布的2022年第四季度财报。若该公司业绩不及预期,市场可能会趁此获利了结,进一步加剧股价回落。此外,由于股价节节攀升,HIMS的期权隐含波动率显著增加,尤其是临近到期的合约。这意味着,预期的未来波动加大,为期权卖家们创造了良机。因此,投资者需格外警惕市场波动风险的上升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.